Publications

Original articles and reviews

 

Stegmann KM, Dickmanns A, Gerber S, Nikolova V, Klemke L, Manzini V, Schlösser D,
Bierwirth C, Freund  J, Sitte M, Lugert R, Salinas G, Görlich D, Wollnik B, Groß U and Dobbelstein M. (2020) The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models. BioRxiv (accepted 10.1101/2020.07.18.210013)

Choo AMY, Schlösser D, Manzini V, Magerhans A and Dobbelstein M. (2020)
The integrated stress response induces R-loops and hinders replication fork progression. Cell Death Dis. 2020 Jul 16;11(7):538. doi: 10.1038/s41419-020-2727-2. PMID: 32678076
PubMed
Choo JAMY, Schlösser D, Manzini V, Magerhans A, Dobbelstein M. Cell Death Dis. 2020 Jul 31;11(7):608. doi: 10.1038/s41419-020-02817-y. PMID: 32737284

Wohlberedt K, Klusmann I, Derevynako PK, Henningsen K, Choo AMY, Manzini V, Magerhans A, Giansanti C, Eischen CM, Jochemsen AG and Dobbelstein M. (2020) 
Mdm4 Supports DNA Replication in a p53-independent Fashion.  Oncogene. 2020 Jun;39(25):4828-4843. doi: 10.1038/s41388-020-1325-1. Epub 2020 May 19. PMID: 32427989

Müller A, Dickmanns A, Resch C, Schäkel K, Hailfinger S, Dobbelstein M, Schulze-Osthoff K, Kramer D. (2020) The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis. J Clin Invest 2020  (accepted 10.1172/JCI134217)

Dobbelstein M, Levine AJ. Mdm2: Open questions. (2020) Cancer Sci. 2020 Jul;111(7):2203-2211. doi: 10.1111/cas.14433. Epub 2020 Jun 11. PMID: 32335977 

Wildung M, Esser TU, Grausam KB, Wiedwald C, Volceanov-Hahn L, Riedel D, Beuermann S, Li L, Zylla J, Guenther AK, Wienken M, Ercetin E, Han Z, Bremmer F, Shomroni O, Andreas S, Zhao H, Lizé M. Transcription factor TAp73 and microRNA-449 complement each other to support multiciliogenesis. Cell Death Differ. 2019 May 8. doi: 10.1038/s41418-019-0332-7. [Epub ahead of print]
PubMed

Herold S, Kalb J, Büchel G, Ade CP, Baluapuri A, Xu J, Koster J, Solvie D, Carstensen A, Klotz C, Rodewald S, Schülein-Völk C, Dobbelstein M, Wolf E, Molenaar J, Versteeg R, Walz S, Eilers M. Recruitment of BRCA1 limits MYCN-driven accumulation of stalled RNA polymerase. Nature. 2019 Mar 20. doi: 10.1038/s41586-019-1030-9. [Epub ahead of print]
PubMed

Klusmann I, Wohlberedt K, Magerhans A, Teloni F, Korbel JO, Altmeyer M, Dobbelstein M: Chromatin modifiers Mdm2 and RNF2 prevent RNA:DNA hybrids that impair DNA replication. Proc Natl Acad Sci U S A. 2018 Nov 27;115(48):E11311-E11320. doi: 10.1073/pnas.1809592115. Epub 2018 Nov 9.
PubMed

Kari V, Mansour WY, Raul SK, Baumgart SJ, Mund A, Grade M, Sirma H, Simon R, Will H, Dobbelstein M, Dikomey E, Johnsen SA: Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness. EMBO Rep. 2018 Oct;19(10). pii: e46783. doi: 10.15252/embr.201846783. (Erratum)
PubMed

Sriraman A, Dickmanns A, Najafova Z, Johnsen SA, Dobbelstein M: CDK4 inhibition diminishes p53 activation by MDM2 antagonists. Cell Death Dis. 2018 Sep 11;9(9):918. doi: 10.1038/s41419-018-0968-0.
PubMed

Kramer D, Stark N, Schulz-Heddergott R, Erytch N, Edmunds S, Roßmann L, Bastians H, Concin N, Moll UM, Dobbelstein M: Correction: Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells. Cell Death Differ. 2018 Sep 3. doi: 10.1038/s41418-018-0190-8. [Epub ahead of print]
PubMed

Schulz-Heddergott R, Stark N, Edmunds SJ, Li J, Conradi LC, Bohnenberger H, Ceteci F, Greten FR, Dobbelstein M, Moll UM: Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion. Cancer Cell. 2018 Aug 13;34(2):298-314.e7. doi: 10.1016/j.ccell.2018.07.004.
PubMed

Li Y, Köpper F, Dobbelstein M: Inhibition of MAPKAPK2/MK2 facilitates DNA replication upon cancer cell treatment with gemcitabine but not cisplatin. Cancer Lett. 2018 Apr 25. pii: S0304-3835(18)30297-0. doi: 10.1016/j.canlet.2018.04.030. [Epub ahead of print]
PubMed

Wienken M, Moll UM, Dobbelstein M: Mdm2 as a chromatin modifier. J Mol Cell Biol. 2017 Feb 1;9(1):74-80. Review.
PubMed

Kramer D, Stark N, Schulz-Heddergott R, Erytch N, Edmunds S, Roßmann L, Bastians H, Concin N, Moll UM, Dobbelstein M: Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells. Cell Death Differ. 2017 Feb;24(2):300-316.
PubMed

Klusmann I, Rodewald S, Müller L, Friedrich M, Wienken M, Li Y, Schulz-Heddergott R, Dobbelstein M: p53 Activity Results in DNA Replication Fork Processivity. Cell Rep. 2016 Nov 8;17(7):1845-1857.
PubMed

Sriraman A, Li Y, Dobbelstein M: Fortifying p53 - beyond Mdm2 inhibitors. Aging (Albany NY). 2016. Sep 29;8(9):1836-1837.
PubMed

Kari V, Mansour WY, Raul SK, Baumgart SJ, Mund A, Grade M, Sirma H, Simon R, Will H, Dobbelstein M, Dikomey E, Johnsen SA: Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness. EMBO Rep. 2016 Sep 5. pii: e201642352. [Epub ahead of print]
PubMed

Sriraman A, Radovanovic M, Wienken M, Najafova Z, Li Y, Dobbelstein M: Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity. Oncotarget. 2016 May 11. doi: 0.18632/oncotarget.9302. [Epub ahead of print]
PubMed

Krönung SK, Beyer U, Chiaramonte ML, Dolfini D, Mantovani R, Dobbelstein M: LTR12 promoter activation in a broad range of human tumor cells by HDAC inhibition. Oncotarget. 2016 May 9. doi: 10.18632/oncotarget.9255. [Epub ahead of print]
PubMed

Beyer U, Krönung SK, Leha A, Walter L, Dobbelstein M: Comprehensive identification of genes driven by ERV9-LTRs reveals TNFRSF10B as a re-activatable mediator of testicular cancer cell death. Cell Death Differ. 2016 Jan;23(1):64-75. doi: 10.1038/cdd.2015.68. Epub 2015 May 29.
PubMed

Wienken M, Dickmanns A, Nemajerova A, Kramer D, Najafova Z, Weiss M, Karpiuk O, Kassem M, Zhang Y, Lozano G, Johnsen SA, Moll UM, Zhang X, Dobbelstein M: MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53. Mol Cell. 2016 Jan 7;61(1):68-83. doi: 10.1016/j.molcel.2015.12.008. Epub 2015 Dec 31.
PubMed

Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, Lozano G, Dobbelstein M, Moll UM: Corrigendum: Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature. 2015 Nov 19;527(7578):398.
PubMed

Kosinsky RL, Wegwitz F, Hellbach N, Dobbelstein M, Mansouri A, Vogel T, Begus-Nahrmann Y, Johnsen SA: Usp22 deficiency impairs intestinal epithelial lineage specification in vivo. Oncotarget. 2015 Nov 10;6(35):37906-18.
PubMed

Li Y, Saini P, Sriraman A, Dobbelstein M: Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors. Oncotarget. 2015 Oct 20;6(32):32339-52.
PubMed

Schmidt F, Karnitz LM, Dobbelstein M: G2E3 attenuating replicative stress. Aging (Albany NY). 2015 Aug;7(8):527-8.
PubMed

Zhang X, Schulz R, Edmunds S, Krüger E, Markert E, Gaedcke J, Cormet-Boyaka E, Ghadimi M, Beissbarth T, Levine AJ, Moll UM, Dobbelstein M: MicroRNA-101 Suppresses Tumor Cell Proliferation by Acting as an Endogenous Proteasome Inhibitor via Targeting the Proteasome Assembly Factor POMP. Mol Cell. 2015 Jul 16;59(2):243-57.
PubMed

Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, Lozano G, Dobbelstein M, Moll UM: Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature. 2015 Jul 16;523(7560):352-6.
PubMed

Dobbelstein M, Sørensen CS: Exploiting replicative stress to treat cancer. Nat Rev Drug Discov. 2015 Jun;14(6):405-23.
PubMed

Saini P, Li Y, Dobbelstein M: Wee1 and Chk1 – crosstalk between key players in replicative stress. Genes Cancer. 2015 May;6(5-6):182-3.
PubMed

Saini P, Li Y, Dobbelstein M: Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress.  Oncotarget. 2015 May 30;6(15):13072-87.
PubMed

Srinivas US, Dyczkowski J, Beißbarth T, Gaedcke J, Mansour WY, Borgmann K, Dobbelstein M: 5-Fluorouracil sensitizes colorectal tumor cells towards double stranded DNA breaks by interfering with homologous recombination repair. Oncotarget. 2015 May 20;6(14):12574-86.
PubMed

Gogiraju R, Xu X, Bochenek ML, Steinbrecher JH, Lehnart SE, Wenzel P, Kessel M, Zeisberg EM, Dobbelstein M, Schäfer K: Endothelial p53 deletion improves angiogenesis and prevents cardiac fibrosis and heart failure induced by pressure overload in mice. J Am Heart Assoc. 2015 Feb 24;4(2). pii: e001770. doi: 10.1161/JAHA.115.001770.
PubMed

Kramer D, Schön M, Bayerlová M, Bleckmann A, Schön MP, Zörnig M, Dobbelstein M: A pro-apoptotic function of iASPP by stabilizing p300 and CBP through inhibition of BRMS1 E3 ubiquitin ligase activity. Cell Death Dis. 2015 Feb 12;6:e1634. doi: 10.1038/cddis.2015.17.
PubMed

Schmidt F, Kunze M, Loock AC, Dobbelstein M: Screening analysis of ubiquitin ligases reveals G2E3 as a potential target for chemosensitizing cancer cells. Oncotarget. 2015 Jan 20;6(2):617-32.
PubMed

Keitel U, Scheel A, Thomale J, Halpape R, Kaulfuß S, Scheel C, Dobbelstein M: Bcl-xL mediates therapeutic resistance of a mesenchymal breast cancer cell subpopulation. Oncotarget. 2014 Dec 15;5(23):11778-91.
PubMed

Keitel U, Scheel C, Dobbelstein M: Overcoming EMT-driven therapeutic resistance by BH3 mimetics. Oncoscience. 2014 Nov 5;1(11):706-8.
PubMed

Landmann H, Proia DA, He S, Ogawa LS, Kramer F, Beißbarth T, Grade M, Gaedcke J, Ghadimi M, Moll U, Dobbelstein M: UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib. Cell Death Dis. 2014 Sep 11;5:e1411.
PubMed

Song R, Walentek P, Sponer N, Klimke A, Lee JS, Dixon G, Harland R, Wan Y, Lishko P, Lize M, Kessel M, He L: miR-34/449 miRNAs are required for motile ciliogenesis by repressing cp110. Nature. 2014 Jun 5;510(7503):115-20.
PubMed

Holembowski L, Kramer D, Riedel D, Sordella R, Nemajerova A, Dobbelstein M, Moll UM. TAp73 is essential for germ cell adhesion and maturation in testis. J Cell Biol. 2014 Mar 31;204(7):1173-90.
PubMed

Dobbelstein M, Moll U: Targeting tumour-supportive cellular machineries in anticancer drug development. Nat Rev Drug Discov. 2014 Feb 28;13(3):179-96. doi: 10.1038/nrd4201.
PubMed

Köpper F, Binkowski AM, Bierwirth C, Dobbelstein M: The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells. Cell Cycle. 2014 Feb 21;13(6).
PubMed

Schulz R, Streller F, Scheel AH, Rüschoff J, Reinert MC, Dobbelstein M, Marchenko ND, Moll UM: HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer. Cell Death Dis. 2014 Jan 2;5:e980
PubMed

Köpper F, Bierwirth C, Schön M, Kunze M, Elvers I, Kranz D, Saini P, Menon MB, Walter D, Sørensen CS, Gaestel M, Helleday T, Schön MP, Dobbelstein M: Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity. Proc Natl Acad Sci USA. 2013 Oct 15;110(42):16856-61
PubMed

Salendo J, Spitzner M, Kramer F, Zhang X, Jo P, Wolff HA, Kitz J, Kaulfuß S, Beißbarth T, Dobbelstein M, Ghadimi M, Grade M, Gaedcke J: Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g. Radiother Oncol. 2013 Sep;108(3):451-7.
PubMed

Dobbelstein M: Interchanging heads: p53 re-composes the DREAM/MMB complex to repress transcription. Cell Cycle. 2013 Jan 1;12(1):11
PubMed

Gallinas Suazo C, Lizé M: MIR449A (microRNA 449a). Atlas Genet Cytogenet Oncol Haematol, 2013 17(3):188-192.

Schulz R, Dobbelstein M, Moll UM: HSP90 inhibitor antagonizing MIF: The specifics of pleiotropic cancer drug candidates.  Oncoimmunology. 2012 Nov 1;1(8):1425-1426.
PubMed

Kranz D, Dobbelstein M: A killer promoting survival: p53 as a selective means to avoid side effects of chemotherapy. Cell Cycle. 2012 Jun 1;11(11):2053-4
PubMed

Pletz N, Schön M, Ziegelbauer K, Emmert S, Liu N, Dobbelstein M, Schön MP: Doxorubicin-induced activation of NF-κB in melanoma cells is abrogated by inhibition of IKKβ, but not by a novel IKKα inhibitor. Exp Dermatol. 2012 Apr;21(4):301-4
PubMed

Schulz R, Marchenko ND, Holembowski L, Fingerle-Rowson G, Pesic M, Zender L, Dobbelstein M, Moll UM: Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression. J Exp Med. 2012 Feb 13;209(2):275-89.
PubMed

Lizé M, Klimke A, Dobbelstein M: MicroRNA-449 in cell fate determination. Cell Cycle. 2011 Sep 1;10(17):2874-82
PubMed

Knöll, R., Linke, WA, Zou P., Miocic, S., Kostin, S., Buyandelger B., Ku, CH, Neef, S., Bug, M., Schäfer, K., Knöll G., Felkin, LE, Wessels, J., Toischer, K., Hagn, F., Kessler, H., didié, M., Quentin T., Maier LS., Teucher N., Unsöld, B., Schmidt A., Birks EJ., Gunkel S., Lang, P., Granzier, H., Zimmermann WH., Field LJ, Faulkner, G., Dobbelstein M., Barton PJR., Sattler M., wilmanns M., Chien KR (2011) Telethonin deficiency is associated with maladaptation to biomechanical stress in the Mammalian heart. Circ Res (Internet-Ausgabe), epub ahead of print
PubMed

U. Beyer, M. Dobbelstein: Non-hominid TP63 lacks retroviral LTRs but contains a novel conserved upstream exon. Cell Cycle 2011 10(12),
PubMed

M. Bug, M. Dobbelstein: Anthracyclines induce the accumulation of mutant p53 through E2F1-dependent and -independent mechanisms. Oncogene 2011 (28).
PubMed

U. Beyer, J. Moll-Rocek, UM. Moll, M. Dobbelstein: Endogenous retrovirus drives hitherto unknown proapoptotic p63 isoforms in the mal germ line of humans and great apes. Proc Natl Acad Sci USA 2011 (99: 3624 - 9
PubMed

L. Holembowski, R. Schulz, F. Talos, A. Scheel, S. Wolff, M. Dobbelstein, UM. Moll: While p73 is essential, p63 is completely dispensable for the development of the central nervous system. Cell Cycle 2011 10(4): 680 - 9
PubMed

I. Savelyva, M. Dobbelstein: Infection with E1B-mutant adenovirus stabilizes p53 but blocks p53 acetylation and activity through E1A. Oncogene 2011 30 (7): 865 - 75 
PubMed

M. Lizé, C. Herr, A. Klimke, R. Bals, M. Dobbelstein: microRNA-449a levels increase by serveral orders of magnitude during mucociliary differentiation of airway epithelia. Cell Cycle 2010 9(22): 4579 - 83
PubMed

I. Drewelus, C. Göpfert, C. Hippel, A. Dickmanns, K. Damianitsch, T. Pieler, M. Dobbelstein: p63 antagonizes Wnt-induced transcription. Cell Cycle 2010 9(3): 580 - 587
PubMed

M. Morawska-Onyszczuk, K. Bienkowska-Szewczyk , M. Dobbelstein: Self-association of adenovirus type 5 E1B-55 kDa as well as p53 is essential for their mutual interaction. Oncogene 2009: 461
PubMed

M. Lizé, S. Pilarski, M. Dobbelstein: E2F1-inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis. Cell Death Diff 2009 : 1-7
PubMed

G. Wolff, F. Talos, G. Palachios, U. Beyer, M. Dobbelstein,  UM. Moll: The alpha/beta carboxy-terminal domains of p63 are required for skin and limb development. New insights from the Bdrm2 mouse which is no a complete p63 knockout but expresses p63 gamma-like proteins. Cell Death Diff 2009  16(8): 1073 - 4
PubMed

F. Talos, S. Wolff, U. Beyer, M. Dobbelstein, UM. Moll: BRDM2-an aberrant hypomorphic p63 allele. Cell Death Diff 2009
PubMed

AH. Scheel, U. Beyer, R. Agami, M. Dobbelstein: Immunofluorescence-based screening identifies germ cell associated microRNA 302 as an antagonist to p63 expression.
Cell Cycle 2209 8(9): 1 - 7
PubMed

SA. Goerges, BN. Chau, CJ. Braun, X. Zhang, M. Dobbelstein: Cell cycle arrest or apoptosis by p53: are microRNAs-192/215 and -34 making the decision? Cell Cycle 2009 8(5): 680 -1
PubMed

CJ.Braun, X. Zhang, I. Savelyeva, S. Wolff, UM. Moll, T. Schepeler, TF. Örntoft. CL. Andersen, M. Dobbelstein: p53-Responsive micrornas192 and 215 are capable of inducing cell cycle arrest. Cancer Res. 2008 68(24); 10094 - 104A
PubMed

D. Kranz, C. Dohmesen and M. Dobbelstein: BRCA 1 and Tip60 determine the cellular response to ultraviolet irradiation through distinct pathways. J.Cell Biol. 2008 182(1), 197 - 213.
PubMed

Gurtner A, Fuschi P, Magi F, Colussi C, Gaetano C, Dobbelstein M, Sacchi A, Piaggio G.: NF-Y dependent epigenetic modifications discriminate between proliferating and postmitotic tissue. PLoS ONE. 2008 Apr 23;3(4):e2047.
PubMed

C. Dohmesen, M. Koeppel and M. Dobbelstein (2008 ): Inhibition of Mdm2-mediated neddylation by Tip60. Cell Cycle. 2008 Jan;7(2):222-31.
PubMed

D. Kranz and M. Dobbelstein (2006):  Non-genotoxic p53 activation protects cells against S phase specific chemotherapy. Cancer Research 66, 10274-10280
PubMed

C. Möritz and M. Dobbelstein (2006): The E1A genes of adenovirus type 2 and type 5 are expressed at different levels. Archives of Virology 151, 1085-1092
PubMed

M. Schümann and M. Dobbelstein (2006): Activating Ras mutations fail to ensure efficient replication of adenovirus mutants lacking VA-RNA. Cell Cycle 5, 315-321
PubMed

M. Schümann and M.Dobbelstein (2006): Adenovirus-induced ERK phosphorylation during the late phase of infection enhances viral protein levels and virus progeny. Cancer Research 66, 1282 – 1288
PubMed

G. Horn and M. Dobbelstein (2005): Enhanced cytotoxicity without internuclear spread of adenovirus upon cell fusion by measles virus glycoporteins. Journal of Virology, 79, 1911-1917
PubMed

M. Dobbelstein, S. Strano, J. Roth, and G. Blandino (2005): p73-induced apoptosis – a question of compartmentalization and cooperation. Biochemical and Biophysical Research Communications 331, 688-693
PubMed

C. Imbriano, A. Gurtner, F. Cocchiarella, S. Di Agostino, V. Basile, M. Gostissa, M. Dobbelstein, G. Del Sal, G.Piaggio and R. Mantovani (2005): Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters. Molecular and Cellular Biology 25, 3737-3751
PubMed

G. Blandino and M. Dobbelstein * (2004): p73 and p63 – Why do we still need them? Cell Cycle 3, 886-894 *corresponding author
Pubmed

U. Hobom and M. Dobbelstein (2004): E1B-55-kilodalton protein is not required to block p53-induced transcription during adenovirus infection. J Virol. 2004 Jul;78(14):7685-97.
PubMed

M. Dobbelstein (2004): Replicating adenoviruses in cancer therapy. Current topics in Microbiology and Immunology, CTMI 273, 291-334
PubMed

A. Contente, H. Zischler, A. Einspanier and M. Dobbelstein (2003): A promoter that acquired p53-response during primate evolution. Cancer Research 63, 1756-1758
PubMed

J. Roth, C. Lenz-Stöppler, A. Contente, K. Löhr, P. Koch, and M. Dobbelstein (2003): Reactivation of mutant p53 by a one-hybrid adaptor protein. Cancer Research 63, 3904-3908
PubMed

K. Löhr, C. Möritz, A. Contente and M. Dobbelstein (2003): p21/CDKN1A is necessary and sufficient for negative regulation of transcription by p53. Journal of Biological Chemistry 278, 32507-32516
PubMed

A. Waltermann, N. N. Kartasheva, and M. Dobbelstein (2003): Differential regulation of p63 and p73 expression. Oncogene 22, 5686-5693
PubMed

K. Löhr, O. Hartmann, H. Schäfer, and M. Dobbelstein (2003): Mutual interference of adenovirus infection and the expression of MYC. Journal of Virology 77, 7936-7944
PubMed

N. N. Kartasheva, C. Lenz-Bauer, O. Hartmann, H. Schäfer, M. Eilers, and M. Dobbelstein (2003): DeltaNp73 can modulate the expression of numerous genes in a p53-independent fashion. Oncogene 22, 8246-8254
PubMed

M. Dobbelstein (2003): Viruses in therapy – royal road or dead end? Virus Research 92, 219-221 PubMed

J. Roth and M. Dobbelstein (2003): Interaction of p53 with the adenovirus E1B-55 kDa protein, Volume Methods in p53 molecular biology (Editor: Swati Palit Deb). Invited review Methods in Molecular Biology 234, 135-150
PubMed

A. Contente, A. Dittmer, M. C. Koch, J. Roth, and M. Dobbelstein (2002): A polymorphic microsatellite that mediates induction of the PIG3 gene by p53. Nature Genetics 30, 315-320
PubMed

P. S. Holm, S. Bergmann, K. Jürchott, H. Lage, K. Brand, A. Ladhoff, K. Mantwill, D. T. Curiel, M. Dobbelstein, M. Dietel, B. Gänsbacher, H.-D. Royer (2002): YB-1 relocates to the nucleus in adenovirus infected cells and facilitates viral replication by inducing E2 gene expression through the E2 late promoter. Journal of Biological Chemistry 277, 10427-10434
PubMed

N. N. Kartasheva, A. Contente, C. Lenz-Stöppler, J. Roth, and M. Dobbelstein (2002): p53 induces the expression of its antagonist p73 Delta N, establishing an autoregulatory feedback loop. Oncogene 21, 4715-4727
PubMed

C. Löber, C. Lenz-Stöppler and M. Dobbelstein (2002): Adenovirus-E1-transformed cells grow despite the continuous presence of transcriptionally active p53. Journal of General Virology 83, 2047-2057.
PubMed

P. Koch, J. Gatfield, C. Löber, U. Hobom, C. Lenz-Stöppler, J. Roth and M. Dobbelstein (2001): Efficient replication of adenovirus despite the overexpression of active and nondegradable p53. Cancer Research 61, 5941-5947
PubMed

S. Wienzek and M. Dobbelstein (2001): Viral and cellular factors that target the promyelocytic leukemia oncogenic domains strongly activate a glucocorticoid-responsive promoter. Journal of Virology 75, 5391-5397
PubMed

S. Wienzek, J. Roth and M. Dobbelstein (2000): The E1B-55 kDa oncoproteins of adenovirus type 5 and type 12 inactivate and relocalize p53 but not p51 and p73, and cooperate with the E4orf6 proteins to destabilize p53. Journal of Virology 74, 764-772
PubMed

S. Weigel and M. Dobbelstein (2000): The nuclear export signal within the E4orf6 protein of adenovirus type 5 supports virus replication and cytoplasmic accumulation of viral mRNA. Journal of Virology 74, 193-202
PubMed

S. Ristea, M. Dobbelstein, and J. Roth (2000): The Rev protein of Human Immunodeficiency Virus type I and the cellular exportin 1 protein relocalize each other to a subnucleolar structure. AIDS Research and Human Retroviruses 16, 857-865
PubMed

J. Roth, P. Koch, A. Contente and M. Dobbelstein (2000): Tumor-derived mutations of p53’s DNA-binding domain result in a phenotype similar to deletion of the proline-rich domain. Oncogene, 19,1834-1842
PubMed

C. König, J. Roth, and M. Dobbelstein (1999): The adenovirus type 5 E4orf3 protein relieves p53-inhibition by E1B-55 kDa. Journal of Virology 73, 2253-2262
PubMed

M. Dobbelstein, S. Wienzek, C. König, and J. Roth (1999): Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. Oncogene 18, 2101-2106
PubMed

J. Roth and M. Dobbelstein (1999): Failure of viral oncoproteins to target the p53-homologue p51A. Journal of General Virology 80, 3251-3255
PubMed

J. Roth*, M. Dobbelstein*, D. Freedman, T. Shenk, and A. J. Levine (1998): Nucleo-cytoplasmic shuttling of the hdm2-oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO Journal 17, 554-564, IF 10,7  *equal contributors
PubMed

J. Roth, C. König, S. Wienzek, S. Weigel, S. Ristea, and M. Dobbelstein (1998): Inactivation of p53 but not p73 by adenovirus type 5 E1B 55-kilodalton and E4 34-kilodalton oncoproteins. Journal of Virology 72, 8510-8516,
PubMed

M. Dobbelstein and J. Roth. (1998): The large T antigen of simian virus 40 binds and inactivates p53 but not p73. Journal of General Virology 79, 3079-3083
PubMed

M. Dobbelstein*, J. Roth*, W. T. Kimberly, A. J. Levine, and T. Shenk (1997): Nuclear export of the adenoviral oncoproteins E1B-55 kD and E4-34 kD. EMBO Journal 16, 4276-4284, IF 10,7  * equal contributors
PubMed

J. Roth and M. Dobbelstein (1997): Export of Hepatitis B Virus RNA on a Rev-like pathway. Journal of Virology 71, 8933-8939
PubMed

M. Dobbelstein and T. Shenk (1996): Protection against apoptosis by the vaccinia virus SPI-2 (B13R) gene product. Journal of Virology 70, 6479-6485
PubMed

B. Elenbaas, M. Dobbelstein, J. Roth, T. Shenk, and A. J. Levine (1996): The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Molecular Medicine 2, 439-451
PubMed

M. Dobbelstein and T. Shenk (1995): In vitro selection of RNA ligands for the ribosomal L22 protein associated with Epstein-Barr virus-expressed RNA by using randomized and cDNA-derived RNA libraries. Journal of Virology 69, 8027-8034
PubMed

M. Dobbelstein, A. K. Arthur, S. Dehde, K. van Zee, A. Dickmanns, and E. Fanning (1992): Intracistronic complementation reveals a new function of SV40 T antigen that co-operates with Rb and p53 binding to stimulate DNA synthesis in quiescent cells. Oncogene 7, 837-847
PubMed

 

M. Dobbelstein: Molekulare Medizin. in Consilium Cedip Practicum, 790-800 (editions in 1994, 1996, 1998, 1999, 2002)

M. Dobbelstein, J. Roth-Dobbelstein, R. Heilbronn, A. Heim, T. Schulz: Adenoviren. In: Diagnostik und Therapie von Viruskrankheiten, Leitlinien der Gesellschaft für Virologie, 28-33

 

Scientific correspondence

M. Dobbelstein and E. Bridge (2000). The nuclear export signal within the adenovirus E4orf6 protein contributes to several steps in the viral life cycle. Journal of Virology 74, 12000-12001, IF 5,2